Article

Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists.

Department of Medicinal Chemistry, Merck & Co. Inc., PO Box 2000, Rahway, NJ 07065, USA.
Bioorganic & medicinal chemistry letters (impact factor: 2.65). 05/2011; 21(10):2911-5. DOI:10.1016/j.bmcl.2011.03.069
Source: PubMed

ABSTRACT A series of six-membered heterocycle carboxamides were synthesized and evaluated as cholecystokinin 1 receptor (CCK1R) agonists. A pyrimidine core proved to be the best heterocycle, and SAR studies resulted in the discovery of analog 5, a potent and structurally diverse CCK1R agonist.

0 0
 · 
0 Bookmarks
 · 
43 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

analog 5
 
CCK1R
 
cholecystokinin 1 receptor
 
pyrimidine core
 
six-membered heterocycle carboxamides
 
structurally diverse CCK1R agonist